ACB vs. CDXC, BTMD, MDWD, FTLF, MNMD, USNA, CGC, CRON, AMRN, and ADCT
Should you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include ChromaDex (CDXC), biote (BTMD), MediWound (MDWD), FitLife Brands (FTLF), Mind Medicine (MindMed) (MNMD), USANA Health Sciences (USNA), Canopy Growth (CGC), Cronos Group (CRON), Amarin (AMRN), and ADC Therapeutics (ADCT). These companies are all part of the "medical" sector.
ChromaDex (NASDAQ:CDXC) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.
ChromaDex received 152 more outperform votes than Aurora Cannabis when rated by MarketBeat users. Likewise, 63.99% of users gave ChromaDex an outperform vote while only 59.44% of users gave Aurora Cannabis an outperform vote.
ChromaDex currently has a consensus price target of $6.00, indicating a potential upside of 72.41%. Given Aurora Cannabis' higher probable upside, equities analysts clearly believe ChromaDex is more favorable than Aurora Cannabis.
ChromaDex has higher earnings, but lower revenue than Aurora Cannabis. ChromaDex is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
ChromaDex has a net margin of -4.24% compared to ChromaDex's net margin of -48.82%. Aurora Cannabis' return on equity of -12.61% beat ChromaDex's return on equity.
15.4% of ChromaDex shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 10.6% of ChromaDex shares are owned by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
ChromaDex has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500.
In the previous week, ChromaDex had 7 more articles in the media than Aurora Cannabis. MarketBeat recorded 19 mentions for ChromaDex and 12 mentions for Aurora Cannabis. ChromaDex's average media sentiment score of 1.13 beat Aurora Cannabis' score of 0.24 indicating that Aurora Cannabis is being referred to more favorably in the news media.
Summary
ChromaDex beats Aurora Cannabis on 12 of the 16 factors compared between the two stocks.
Get Aurora Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurora Cannabis Competitors List
Related Companies and Tools
